Drugs & Aging

, Volume 30, Issue 10, pp 783–792 | Cite as

Successes and Failures for Drugs in Late-Stage Development for Alzheimer’s Disease

  • Camryn Berk
  • Marwan N. Sabbagh
Review Article


To date, symptomatic medications prevail as the mainstay of treatment options for Alzheimer’s disease (AD). There have been tremendous investments made to increase the numbers of drugs approved and the targets engaged, in an effort to alter the disease course or pathophysiology of AD. Unfortunately, almost all studies have not met expectations and no new drug (beyond medical foods) has been approved for the treatment of AD in the last decade. This review is a comparison of novel AD therapies in the late phases of clinical testing, including recent high-profile clinical failures, and agents in development with relatively unexplored mechanisms of action, with a focus on their potential as therapeutic agents and their proposed advantages over the treatments currently in use.


Transcranial Magnetic Stimulation Mini Mental State Examination Score BACE Inhibitor Gamma Secretase Masitinib 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Supported by the Banner Sun Health Research Institute, NIA P30 AG 019610 and the Arizona Alzheimer’s Research Consortium.


Camryn Berk has no disclosures relating to this manuscript. Dr Sabbagh receives contract/grant support from Lilly, Avanir, Pfizer, Eisai, Functional Neuromodulation, Genentech, Piramal, Avid and Elan. Dr Sabbagh is an advisor/consultant to Biogen, Piramal and Eisai. Dr Sabbagh receives royalties from Wiley and TenSpeed. Neither author received compensation in the drafting of this manuscript.


  1. 1.
    Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. 2003;60:1119–22.CrossRefPubMedGoogle Scholar
  2. 2.
    Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology. 1991;41(4):479–86.CrossRefPubMedGoogle Scholar
  3. 3.
    Atri A, Molinuevo JL, Lemming O, Wirth Y, Pulte I, Wilkinson D. Memantine in patients with Alzheimer’s disease receiving donepezil: new analyses of efficacy and safety for combination therapy. Alzheimers Res Ther. 2013;5(1):6.CrossRefPubMedGoogle Scholar
  4. 4.
    Downing N, Aminawung A, Shah N, et al. Regulatory review of novel therapeutics—comparison of three regulatory agencies. N Engl J Med. 2012;366:2284–93.CrossRefPubMedGoogle Scholar
  5. 5.
    Hock C, Konietzko U, Streffer JR, et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer’s disease. Neuron. 2003;38(4):547–54.CrossRefPubMedGoogle Scholar
  6. 6.
    Alvarez X, Cacabelos R, Sampedro C, et al. Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer’s disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin. Eur J Neurol. 2011;18(1):59–68.CrossRefPubMedGoogle Scholar
  7. 7.
    Piette F, Belmin J, Vincent H, et al. Masitinib as an adjunct therapy for mild-to-moderate Alzheimer’s disease: a randomized, placebo-controlled phase 2 trial. Alzheimers Res Ther. 2011;3(2):16.CrossRefPubMedGoogle Scholar
  8. 8.
    Landhuis L. Will tau drug show its true colors in phase 3 trials? Alzheimer Res Forum. October 2, 2012.
  9. 9.
    Rinne JO, Brooks DJ, Rossor MN, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer’s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010;9(4):363–72.CrossRefPubMedGoogle Scholar
  10. 10.
    Juha RO, Brooks DJ, Rossor MN, et al. 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer’s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010;9(4):363–72.CrossRefGoogle Scholar
  11. 11.
    Sperling R, Salloway S, Brooks DJ, et al. Amyloid-related imaging abnormalities in patients with Alzheimer’s disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol. 2012;11(3):241–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Pfizer. Amyloid imaging and safety study of subcutaneous bapineuzumab in subjects with mild to moderate Alzheimer’s disease (SUMMIT AD). NCT01254773.Google Scholar
  13. 13.
    Imbimbo BP, Ottonello S, Frisardi V, et al. Solanezumab for the treatment of mild-to-moderate Alzheimer’s disease. Expert Rev Clin Immunol. 2012;8(2):135–49.CrossRefPubMedGoogle Scholar
  14. 14.
    Goto T, Fujikoshi S, Uenaka K, et al. Solanezumab was safe and well-tolerated for Asian patients with mild-to-moderate Alzheimer’s disease in a multicenter, randomized, open-label, multi-dose study. Alzheimers Dement. 2012;6(4 Suppl):S308.Google Scholar
  15. 15.
    Gelinas DS, DaSilva K, Fenili D, et al. Immunotherapy for Alzheimer’s disease. PNAS. 2004;101(Suppl 2):14657–62.CrossRefPubMedGoogle Scholar
  16. 16.
    Wilkinson K, El Khoury J. Microglial scavenger receptors and their roles in the pathogenesis of Alzheimer’s disease. Int J Alzheimer’s Dis. 2012;2012:Article ID 489456.Google Scholar
  17. 17.
    Willis B, Zhang W, Ayan-Oshodi M, et al. Semagacestat pharmacokinetics are not significantly affected by formulation, food, or time of dosing in healthy participants. J Clin Pharmacol. 2012;52(6):904–13.CrossRefPubMedGoogle Scholar
  18. 18.
    Eriksen JL, Sagi SA, Smith TE, et al. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower amyloid beta 42 in vivo. J Clin Investig. 2003;112(4):440–9.PubMedGoogle Scholar
  19. 19.
    Santa-Maria I, Hernández F, Del Rio J, et al. Tramiprosate, a drug of potential interest for the treatment of Alzheimer’s disease, promotes an abnormal aggregation of tau. Mol Neurodegener. 2007;6(2):17.CrossRefGoogle Scholar
  20. 20.
    Gervais F, Paquette J, Morissette C, et al. Targeting soluble Aβ peptide with tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging. 2007;28(4):537–47.CrossRefPubMedGoogle Scholar
  21. 21.
    DeKosky S, Williamson J, Fitzpatrick A, et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA. 2008;300(19):2253–62.CrossRefPubMedGoogle Scholar
  22. 22.
    Quinn J, Raman R, Thomas R, et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer’s disease: a randomized trial. JAMA. 2010;304(17):1903–11.CrossRefPubMedGoogle Scholar
  23. 23.
    Park S, Jung J, Lee H, et al. The memory ameliorating effects of INM-176, an ethanolic extract of Angelica gigas, against scopolamine- or AB(1–42)-induced dysfunction in mice. J Ethnopharmacol. 2012;143(2):611–20.CrossRefPubMedGoogle Scholar
  24. 24.
    Salloway S, Sperling R, Keren R, et al. A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer’s disease. Neurology. 2011;77(13):1253–62.CrossRefPubMedGoogle Scholar
  25. 25.
    Seo JS, Baek IS, Leem YH, et al. SK-PC-B70M alleviates neurologic symptoms in amyotrophic lateral sclerosis mice. Brain Res. 2011;12(1368):299–307.CrossRefGoogle Scholar
  26. 26.
    Schmidt AM, Sahagan B, Nelson RB, et al. The role of RAGE in amyloid-beta peptide-mediated pathology in Alzheimer’s disease. Curr Opin Investig Drugs. 2009;10(7):672–80.PubMedGoogle Scholar
  27. 27.
    Yan SD, Chen X, Fu J, et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer’s disease. Nature. 1996;382(6593):685–91.CrossRefPubMedGoogle Scholar
  28. 28.
    Yan SD, Bierhaus A, Nawroth PP, Stern DM. RAGE and Alzheimer’s disease: a progression factor for amyloid-beta-induced cellular perturbation? J Alzheimers Dis. 2009;16(4):833–43.PubMedGoogle Scholar
  29. 29.
    Yan SD, Chen X, Walker DG. RAGE: a potential target for a-mediated cellular perturbation in Alzheimers disease. Curr Mol Med. 2007;7(8):735–42.CrossRefPubMedGoogle Scholar
  30. 30.
    Carrano A, Hoozemans JJM, Van der Vies SM, et al. Amyloid beta induces oxidative stress-mediated blood–brain barrier changes in capillary amyloid angiopathy. Antioxid Redox Signal. 2011;15(5):1167–78.CrossRefPubMedGoogle Scholar
  31. 31.
    Hartz AMS, Bauer B, Soldner ELB, et al. Amyloid-β contributes to blood–brain barrier leakage in transgenic human amyloid precursor protein mice and in humans with cerebral amyloid angiopathy. Stroke. 2012;43(2):514–23.CrossRefPubMedGoogle Scholar
  32. 32.
    Kook S-Y, Hong HS, Moon M, et al. Ab1–42–RAGE interaction disrupts tight junctions of the blood–brain barrier via Ca2+–calcineurin signaling. J Neurosci. 2012;32(26):8845–54.CrossRefPubMedGoogle Scholar
  33. 33.
    Deane R, Du Yan S, Submamaryan RK, et al. RAGE mediates amyloid-beta peptide transport across the blood–brain barrier and accumulation in brain. Nat Med. 2003;9(7):907–13.CrossRefPubMedGoogle Scholar
  34. 34.
    Sabbagh MN, Agro A, Bell J, Aisen PS, et al. PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease. Alzheimer Dis Assoc Disord. 2011;25:206–12.CrossRefPubMedGoogle Scholar
  35. 35.
    Chen M, Inestrosa NC, Ross GS, Fernandez HL. Platelets are the primary source of amyloid beta-peptide in human blood. Biochem Biophys Res Commun. 1995;213(1):96–103.CrossRefPubMedGoogle Scholar
  36. 36.
    Evin G, Zhu A, Holsinger RM, Masters CL, Li QX. Proteolytic processing of the Alzheimer’s disease amyloid precursor protein in brain and platelets. J Neurosci Res. 2003;74(4):386–92.CrossRefPubMedGoogle Scholar
  37. 37.
    Li QX, Fuller SJ, Beyreuther K, Masters CL. The amyloid precursor protein of Alzheimer disease in human brain and blood. J Leukoc Biol. 1999;66(4):567–74.PubMedGoogle Scholar
  38. 38.
    Pluta R. Astroglial expression of the beta-amyloid in ischemia–reperfusion brain injury. Ann N Y Acad Sci. 2002;977:102–8.CrossRefPubMedGoogle Scholar
  39. 39.
    Burton T, Liang B, Dibrov A, Amara F. Transcriptional activation and increase in expression of Alzheimer’s beta-amyloid precursor protein gene is mediated by TGF-beta in normal human astrocytes. Biochem Biophys Res Commun. 2002;295(4):702–12.CrossRefPubMedGoogle Scholar
  40. 40.
    Hartlage-Rubsamen M, Zeitschel U, Apelt J, Gartner U, Franke H, Stahl T, Gunther A, Schliebs R, Penkowa M, Bigl V, Rossner S. Astrocytic expression of the Alzheimer’s disease beta-secretase (BACE1) is stimulus-dependent. Glia. 2003;41(2):169–79.CrossRefPubMedGoogle Scholar
  41. 41.
    Craft S, Baker L, Montine T, et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment. Arch Neurol. 2012;69(1):29–38.CrossRefPubMedGoogle Scholar
  42. 42.
    Delrieu J, Ousset PJ, Vellas B, et al. Gantenerumab for the treatment of Alzheimer’s disease. Expert Opin Biol Ther. 2012;12(8):1077–86.CrossRefPubMedGoogle Scholar
  43. 43.
    Ostrowitzki S, Deptula D, Thurfiell L, et al. Mechanism of amyloid removal in patients with Alzheimer’s disease treated with gantenerumab. Arch Neurol. 2012;69(2):198–207.CrossRefPubMedGoogle Scholar
  44. 44.
    Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M. Alzheimer’s disease: clinical trials and drug development. Lancet Neurol. 2010;9(7):702–16. doi: 10.1016/S1474-4422(10)70119-8 (Review. Erratum in: Lancet Neurol. 2011;10(6):501).Google Scholar
  45. 45.
    Boutajangout A, Sigurdsson E, Krishnamurthy P. Tau as a therapeutic target for Alzheimer’s disease. Curr Alzheimer Res. 2011;8(6):666–77.CrossRefPubMedGoogle Scholar
  46. 46.
    Smith G, Laxton A, Tang-Wai D, et al. Increased cerebral metabolism after 1 year of deep brain stimulation in Alzheimer disease. Arch Neurol. 2012;69(9):1141-8.Google Scholar

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  1. 1.The Cleo Roberts Center for Clinical ResearchBanner Sun Health Research InstituteSun CityUSA

Personalised recommendations